CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of three drugs called lenalidomide, subcutaneous (injection under the skin) bortezomib, and dexamethasone (RVD) as a possible treatment for multiple...
Phase 2
Morristown, New Jersey, United States and 7 other locations
in combination with dexamethasone in subjects with newly diagnosed multiple myeloma followed by treatment with a combination of dru...
Phase 2
New York, New York, United States
multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple...
Phase 1, Phase 2
New York, New York, United States and 2 other locations
The purpose of this study is to evaluate three daratumumab dose schedules in participants with Smoldering Multiple Myeloma....
Phase 2
New York, New York, United States and 56 other locations
and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...
Phase 2
New York, New York, United States and 25 other locations
(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...
Phase 3
New York, New York, United States and 145 other locations
This is a first in human, phase 1, multicenter, open-label study to determine the safety and tolerability of IGM-2644 as a single agent in participan...
Phase 1
New York, New York, United States and 4 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Phase 1, Phase 2
Hackensack, New Jersey, United States and 48 other locations
This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and pre...
Phase 1
New York, New York, United States and 5 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...
Phase 1
New York, New York, United States and 9 other locations
Clinical trials
Research sites
Resources
Legal